Anthropic revenue run rate hits $65 billion as IPO plans advance

scanx
Reviewed by
Ritika DScanX News Team
Key Highlights

Anthropic's annualized revenue run rate climbed to $65 billion by July, up seven times from a year ago and surpassing its May figure of $47 billion. Second-quarter preliminary revenue hit $11.5 billion, reflecting a 14-fold year-on-year increase driven by enterprise demand for Claude. The company has filed for an IPO with the SEC.

powered bylight_fuzz_icon
48584045

*this image is generated using AI for illustrative purposes only.

Anthropic, the maker of the Claude artificial intelligence model, reported that its annualized revenue run rate reached $65 billion by the end of July. The figure represents a sevenfold increase from the same period a year earlier and signals accelerating commercial adoption of its enterprise products ahead of a potential public listing.

The company shared the updated metrics with investors over the weekend, according to reports citing sources familiar with the matter. This latest run rate is also significantly higher than the $47 billion figure Anthropic reported in May, indicating rapid month-on-month growth in its top line.

Revenue Acceleration and Enterprise Demand

In addition to the annualized run rate, Anthropic disclosed preliminary revenue for the second quarter of $11.5 billion. This quarterly figure marks a roughly 14-fold increase compared to the same period in the prior year.

Metric Value Comparison
Annualized Revenue Run Rate (July) $65 billion Sevenfold increase YoY
Annualized Revenue Run Rate (May) $47 billion N/A
Q2 Preliminary Revenue $11.5 billion Roughly 14-fold increase YoY

The surge in revenue is driven largely by growing demand from businesses utilizing Claude for coding, research, automation, and other enterprise applications. This performance places Anthropic ahead of rival OpenAI, whose annualized revenue was reported at approximately $40 billion.

What the Numbers Show

The divergence between the Q2 preliminary revenue and the annualized run rate highlights the velocity of Anthropic's recent growth. While the Q2 revenue of $11.5 billion suggests a strong start to the half, the jump from a $47 billion run rate in May to $65 billion in July indicates that monthly revenue growth is outpacing the linear projection of earlier quarters. This acceleration underscores the intensifying competition in the generative AI sector, where Anthropic is now leading in reported revenue scale against key competitors.

IPO Preparations and Valuation

The financial results come as Anthropic prepares for a possible debut on public markets. The company confidentially submitted a draft S-1 registration statement to the Securities and Exchange Commission in June, providing it with the option to go public depending on market conditions.

Anthropic was valued at $965 billion in its latest major funding round, setting high expectations for its initial public offering. However, the company faces ongoing regulatory and government-related challenges, including disputes over the use and export of its AI models. Recent reports indicate that Anthropic projects revenue between $190 billion and $200 billion by 2028.

How will Anthropic's $965 billion private valuation impact investor expectations and potential pricing strategies for its upcoming IPO?

What specific regulatory hurdles regarding AI model exports could delay or complicate Anthropic's timeline for going public?

Can Anthropic sustain its current revenue acceleration trajectory against intensifying competition from OpenAI and other tech giants?

like18
dislike

Anthropic CEO says AI could cure most human disease in 5-10 years

scanx
Reviewed by
Ritika DScanX News Team
Key Highlights

Anthropic CEO Dario Amodei predicts AI could cure most human diseases within five to 10 years, citing personal loss as motivation. He calls for FDA regulatory reforms to speed up drug approvals and urges the industry to deliver tangible medical results to rebuild public trust, acknowledging current shortcomings in meeting high expectations.

powered bylight_fuzz_icon
48541402

*this image is generated using AI for illustrative purposes only.

Anthropic CEO Dario Amodei said artificial intelligence could help cure most human diseases within five to 10 years, arguing that the industry must deliver real breakthroughs in medicine rather than rely on optimistic messaging.

Amodei made the comments in a post on X, responding to criticism that his public messaging has focused disproportionately on AI risks. He cited his 2024 essay "Machines of Loving Grace," which challenged skepticism about AI's potential in health and biology. He also referenced a June 2026 essay, "Policy on the AI Exponential," where he proposed streamlining Food and Drug Administration (FDA) processes to prevent regulatory delays for AI-accelerated drugs.

Personal Motivation and Industry Trust

Amodei linked his urgency to personal experience, noting his father died from Hepatitis C shortly before direct-acting antiviral drugs like sofosbuvir were developed. He stated these drugs could cure 95% of patients and likely would have cured his father.

He acknowledged that predicting cures for most diseases within five to 10 years may sound far-fetched to the public and biologists. However, he emphasized that Anthropic is rapidly increasing efforts in biology and medicine, expecting "early glimmers" of progress in coming months.

What the Numbers Show

The data highlights a divergence between public perception and industry action. Amodei noted that public skepticism reflects a broader crisis of trust in companies and governments. He argued that marketing campaigns promising future benefits are insufficient to counter this skepticism. Instead, he stated that actual cures, such as curing cancer, would be more meaningful than promises. He admitted that AI companies deserve criticism for not yet delivering on their biggest promises, placing the responsibility on the industry to produce tangible results.

Regulatory and Strategic Outlook

Amodei stressed that medical impact requires not just capable AI but also regulatory changes. He proposed ways to streamline FDA processes so that waves of AI-accelerated drugs are not unnecessarily slowed.

He intends to continue speaking honestly about both AI's potential benefits and risks. Amodei said credibility will ultimately come from tangible results rather than promises, and Anthropic will publicize achievements in biology and medicine when they materialize.

How might the FDA respond to Amodei's proposal for streamlining regulatory processes for AI-accelerated drugs, and what new frameworks could emerge?

What specific biological milestones or 'early glimmers' of progress should investors and researchers monitor in the coming months to validate Anthropic's claims?

How will the broader biotech industry adjust its R&D strategies if AI companies successfully demonstrate the ability to cure major diseases within a decade?

like17
dislike

More News on anthropic